Monitoring of nasal permeability during the treatmrnt of patients with overlap syndrome with combined broncholytic drug (ipratropium bromide + salbutamol)

Y. I. Feschenko, L. A. Yashyna, O. J. Lekan, G. V. Sidun (Kiev, Ukraine)

Source: Annual Congress 2001 - Diseases of the airways including SAS
Session: Diseases of the airways including SAS
Session type: Thematic Poster Session
Number: 1510
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. I. Feschenko, L. A. Yashyna, O. J. Lekan, G. V. Sidun (Kiev, Ukraine). Monitoring of nasal permeability during the treatmrnt of patients with overlap syndrome with combined broncholytic drug (ipratropium bromide + salbutamol). Eur Respir J 2001; 16: Suppl. 31, 1510

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pulmonary function and bronchodilator response to albuterol, ipratropium bromide and association of albuterol and ipratropium bromide in children with cystic fibrosis (CF)
Source: Eur Respir J 2003; 22: Suppl. 45, 229s
Year: 2003

Effect of patient age on response to nebulised salbutamol or ipratropium bromide
Source: Annual Congress 2012 - Going with the flow: assessment and evaluation of airway function and its role in patient management
Year: 2012

Cardiopulmonary effects of inhaled ipratropium bromide and its combination with fenoterol in patients with bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 58s
Year: 2002

Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children
Source: Eur Respir J 2004; 24: Suppl. 48, 167s
Year: 2004

A comparison of early bronchodilating responses of Salbutamol, Ipratropium bromide, and the combination of Ipratropium bromide-Salbutamol in stable patients with COPD or asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002

Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 356s
Year: 2007

The combination therapy with inhaled tiotropium bromide and transdermal tulobuterol in COPD improves the peripheral airway function
Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Year: 2010

Reversibility effects of ipratropium bromide and terbutalin sulphate in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 72s
Year: 2001

Comparative study of one-year treatment with salmeterol along, and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructi e pulmonary diseases (COPD)
Source: Eur Respir J 2003; 22: Suppl. 45, 286s
Year: 2003

Sleep architecture in COPD patients during salmeterol versus ipratropium bromide treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 113s
Year: 2004

Comparison of the safety relating to paradoxical bronchoconstriction of ipratropium bromide (IB) alone or combined with fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (CFC-MDI) in
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002

Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Tiotropium bromide (TIO) reduces hospitalizations in patients with COPD who had been refractory to treatment with combined inhaled corticosteroid/long acting beta agonist (ICS/LABA)
Source: Eur Respir J 2005; 26: Suppl. 49, 717s
Year: 2005

Improved delivery of fenoterol plus ipratropium bromide using Respimat(R) compared with a conventional metered dose inhaler
Source: Eur Respir J 2001; 17: 225-232
Year: 2001



Evaluation of bronchodilator response to single dose tiotropium bromide
Source: Eur Respir J 2004; 24: Suppl. 48, 504s
Year: 2004

A comparison of bronchodilating response of salbutamol, ipratropium bromide and the combination of ipratropium-salbutamol in patients with stable chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: Suppl. 33, 59s
Year: 2001

Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study
Source: Annual Congress 2007 - New drugs for COPD
Year: 2007


Efficacy of tiotropium bromide inhalation combined with or without low dose theophylline for moderate to severe stable Chinese COPD patients
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013

Acute effect of formoterol, salmeterol, albuterol, oxitropium bromide and placebo on FEV1, inspiratory capacity and dyspnoea in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 380s
Year: 2001